Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors

Open Access

Peer-reviewed

Research Article

Tong T. Zhao ,

Contributed equally to this work with: Tong T. Zhao, Diane Trinh

Affiliations Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, The Faculty of Medicine and the Department of Biochemistry at the University of Ottawa, Ottawa, Ontario, Canada
⨯
Diane Trinh ,

Contributed equally to this work with: Tong T. Zhao, Diane Trinh

Affiliation Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
⨯
Christina L. Addison,

Affiliations Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, The Faculty of Medicine and the Department of Biochemistry at the University of Ottawa, Ottawa, Ontario, Canada
⨯
Jim Dimitroulakos

* E-mail: jdimitroulakos@ohri.ca

Affiliations Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, The Faculty of Medicine and the Department of Biochemistry at the University of Ottawa, Ottawa, Ontario, Canada
⨯

Reader Comments (0)

Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cytotoxicity
Is the Subject Area "Cytotoxicity" applicable to this article?

Thanks for your feedback.
Actins
Is the Subject Area "Actins" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cytoskeleton
Is the Subject Area "Cytoskeleton" applicable to this article?

Thanks for your feedback.
VEGF signaling
Is the Subject Area "VEGF signaling" applicable to this article?

Thanks for your feedback.
MTT assay
Is the Subject Area "MTT assay" applicable to this article?

Thanks for your feedback.
Mesothelioma
Is the Subject Area "Mesothelioma" applicable to this article?

Thanks for your feedback.